A provider briefing on Bronkaid Max availability in 2026: shortage timeline, prescribing implications, cost data, and tools to help patients.
As a healthcare provider, you may be hearing from patients who are struggling to find Bronkaid Max — the OTC bronchodilator containing 25 mg of Ephedrine Sulfate. While the acute shortage caused by the 2020-2021 reformulation has largely resolved, intermittent availability issues continue to affect patients across the country.
This briefing covers the current state of Bronkaid Max availability, the regulatory context behind the shortage, prescribing implications, and tools you can use to help your patients find this medication or appropriate alternatives.
Bronkaid Max is an over-the-counter sympathomimetic bronchodilator manufactured by Foundation Consumer Healthcare. Each coated caplet contains 25 mg of Ephedrine Sulfate. It is indicated for the temporary relief of mild symptoms of intermittent asthma.
The current formulation replaced the original Bronkaid (Ephedrine Sulfate 25 mg + Guaifenesin 400 mg) following the CARES Act of 2020, which required the removal of the Guaifenesin component. For a clinical overview of the drug's mechanism, see How Does Bronkaid Max Work: Mechanism of Action Explained.
The CARES Act required Foundation Consumer Healthcare to reformulate Bronkaid by removing Guaifenesin. Production of the original Bronkaid ceased, and manufacturing shifted to the new Bronkaid Max formulation.
During the transition period, a nationwide supply disruption left pharmacies without stock for months. Patients reported being unable to find the product at any pharmacy in their area. The disruption was compounded by pandemic-related supply chain pressures.
Distribution recovered through 2022 and into 2023, with most major pharmacy chains resuming stock. However, some pharmacies that dropped the product during the shortage did not resume ordering.
As of 2026, Bronkaid Max is in active production and distribution. No formal FDA shortage listing exists. However, spot shortages at individual pharmacies remain common due to behind-the-counter storage requirements, pharmacy stocking decisions, and the product's niche demand profile.
While Bronkaid Max does not require a prescription, providers should be aware of several clinical considerations:
Ephedrine-containing products are regulated under the Combat Methamphetamine Epidemic Act of 2005. Patients must:
Some states impose additional restrictions, including requiring a prescription for Ephedrine products. Providers in these states may need to write prescriptions for patients who would otherwise purchase it OTC.
Bronkaid Max is not recommended for:
Due to its systemic sympathomimetic effects, Ephedrine carries cardiovascular risks that make it less suitable than selective beta-2 agonists for many patients. For a complete interaction profile, see Bronkaid Max Drug Interactions: What to Avoid.
Current NHLBI asthma guidelines do not include oral Ephedrine as a recommended therapy. Bronkaid Max occupies a role primarily for:
For most patients with persistent or moderate-to-severe asthma, transition to an Albuterol inhaler provides superior clinical outcomes with better safety profile.
Bronkaid Max is available at most major pharmacy chains, including CVS, Walgreens, Walmart, and Rite Aid. However, stock varies significantly by location. Key factors affecting availability include:
Providers can help patients locate the product using Medfinder for Providers, which shows pharmacy-level availability data.
Bronkaid Max remains an affordable OTC option:
For patients where cost is a barrier to prescription alternatives, Bronkaid Max's low price point makes it an accessible option. Generic Albuterol inhalers ($20-$35) are also reasonably priced for patients who can obtain a prescription.
Here are resources you can share with patients or use in your practice:
The OTC asthma treatment landscape is relatively stable in 2026. Bronkaid Max continues to serve as an accessible option for patients with mild asthma who prefer or require OTC access. However, providers should remain aware that:
The most impactful step providers can take is to proactively discuss asthma management options with patients who report using Bronkaid Max, ensuring they have both a plan for finding the medication and awareness of potentially superior prescription alternatives.
Bronkaid Max remains available but intermittently hard to find due to regulatory restrictions and pharmacy stocking decisions rather than a manufacturing shortage. As a provider, you can help your patients by pointing them to availability tools like Medfinder, discussing alternatives when appropriate, and considering prescription rescue inhalers for patients with more than occasional symptoms.
For additional provider resources, see How to Help Your Patients Find Bronkaid Max in Stock: A Provider's Guide and How to Help Patients Save Money on Bronkaid Max.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
